Nuvalent, Inc. announced on April 17 new clinical and preclinical findings for its investigational drug candidate zidesamtinib at the American Association for Cancer Research (AACR) Annual Meeting 2026.
The results are significant because they address treatment options for patients with ROS1-positive non-small cell lung cancer (NSCLC) who have already received tyrosine kinase inhibitors (TKIs), including those with resistance mutations or central nervous system involvement. The company said that these patients often have limited alternatives after standard therapies.
James Porter, Ph.D., Chief Executive Officer at Nuvalent, said, “The strong patient enrollment in our ARROS-1 trial has reflected meaningful investigator enthusiasm for zidesamtinib’s profile and generated a robust data set that enables deep characterization of its activity for patients with ROS1-positive NSCLC beyond our initial pivotal data presentation.” Porter also said, “We’re highly encouraged by these clinical data for patients previously treated with repotrectinib or taletrectinib in our ARROS-1 trial, which we believe further reinforce the medical needs that remain for patients with ROS1-positive NSCLC despite the availability of new treatment options.”
Christopher Turner, M.D., Chief Medical Officer at Nuvalent, said, “Zidesamtinib demonstrated clinically meaningful activity in this heavily pre-treated subgroup, including activity in tumors with the ROS1 G2032R resistance mutation and intracranial complete responses for patients with CNS disease. Importantly, this indicates that ROS1-positive NSCLC tumors may remain ROS1-dependent beyond treatment with repotrectinib or taletrectinib and we believe supports the potential for zidesamtinib, if approved, to provide a clinically meaningful treatment option for patients who have exhausted available therapies.” Turner added that the clinical findings align with preclinical evidence showing improved brain penetrance compared to other treatments.
According to Nuvalent’s statement, the U.S. Food and Drug Administration has accepted a New Drug Application submission for zidesamtinib targeting adults with locally advanced or metastatic ROS1-positive NSCLC who received prior TKI therapy. A Prescription Drug User Fee Act target action date is set for September 18, 2026. The company plans to seek label expansion later in 2026 to include TKI-naïve patients.
Preclinical studies presented showed that among three tested TKIs—zidesamtinib included—the investigational drug demonstrated differentiated brain penetrance and intracranial antitumor activity against resistant mutations when compared to repotrectinib and taletrectinib; however head-to-head clinical trials have not yet been conducted between these agents.
PR Newswire operates in more than 170 countries and supports press release distribution in over 40 languages according to the official website official website. It aims to deliver global reach through its network of newsrooms and influencers as detailed on its official website. PR Newswire features expert editors providing round-the-clock support as noted on their official website, collaborates globally across over half a million media outlets according to their official website, extends operations internationally as described on their official website, and offers services such as AI-enhanced content tools according to information outlined on their official website.
Looking ahead, Nuvalent anticipates commercial launch of zidesamtinib pending regulatory review later in 2026.
